Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiopurine dose reduction or withdrawal during vedolizumab maintenance in ulcerative colitis
ACTRN12618000812291Phase 4Not yet recruiting
- Sponsor
- Concord Repatriation General Hospital
- Start
- Jun 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vedolizumab, azathioprine and mercaptopurine in autoimmune colitis, sponsored by Concord Repatriation General Hospital. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
vedolizumabazathioprinemercaptopurine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ACTRN12618000812291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000812291.